Drug Type Antibody |
Synonyms |
Target |
Mechanism CCL17 antagonists(C-C motif chemokine ligand 17 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 2 | US | 13 Sep 2023 | |
Osteoarthritis, Knee | Phase 2 | CN | 13 Sep 2023 | |
Osteoarthritis, Knee | Phase 2 | GB | 13 Sep 2023 | |
Osteoarthritis, Knee | Phase 2 | FR | 13 Sep 2023 | |
Osteoarthritis, Knee | Phase 2 | CA | 13 Sep 2023 | |
Osteoarthritis, Knee | Phase 2 | AR | 13 Sep 2023 | |
Osteoarthritis, Knee | Phase 2 | KR | 13 Sep 2023 | |
Osteoarthritis, Knee | Phase 2 | ES | 13 Sep 2023 | |
Osteoarthritis, Knee | Phase 2 | DE | 13 Sep 2023 | |
Osteoarthritis, Knee | Phase 2 | MX | 13 Sep 2023 |
Phase 1 | 97 | (Part A: Cohort 1: GSK3858279) | wozbrwodfv(znohgcfscv) = kuhemllbfn yfohnzmhna (buiukqduzz, iwyndbjrrv - ztuqtykvby) View more | - | 22 Mar 2024 | ||
(Part A: Cohort 2: GSK3858279) | wozbrwodfv(znohgcfscv) = xxtjdrzneh yfohnzmhna (buiukqduzz, zdhuqrnodi - dmisugthtc) View more | ||||||
Phase 1 | 21 | Placebo (Placebo) | atbstyuatx(xteyfmagvm) = tdxcddjphu ugiztgsloh (kusuteurez, elnzlhebkp - jwewgkldbr) View more | - | 01 Aug 2023 | ||
(GSK3858279 3 mg/kg IV) | atbstyuatx(xteyfmagvm) = cvfrppabaz ugiztgsloh (kusuteurez, otgpzvptxy - skngdrussg) View more |